Breaking News

OPFI

OppFi

07
Jun

05/12/23 Needham: OppFi price target raised to $3.50 from $2.50 at Needham

03/24/23 DA Davidson: OppFi price target lowered to $2.50 from $3 at DA Davidson

08/11/22 DA Davidson: OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook

08/10/22 DA Davidson: OppFi downgraded to Neutral from Buy at DA Davidson

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	OppFi price target raised to $3.50 from $2.50 at Needham » 08:28 05/12/23 05/12 08:28 05/12/23 08:28 OPFI OppFi $2.06 / +0.05 (+2.49%) Needham analyst Mayank… Needham analyst Mayank Tandon raised the firm's price target on OppFi to $3.50 from $2.50 and keeps a Buy rating on the shares. The company's Q1 results were above expectations on top and bottom line amid improving credit performance and lower expenses, primarily on the marketing front, the analyst tells investors in a research note. While credit environment is expected to remain challenging in the near term, Needham is "encouraged" with OppFi's strong start to FY23. ShowHide Related Items >><< Street Research Earnings On The Fly Events OPFI OppFi $2.06 / +0.05 (+2.49%) 03/24/23 DA Davidson OppFi price target lowered to $2.50 from $3 at DA Davidson 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson OPFI OppFi $2.06 / +0.05 (+2.49%) 05/11/23 OppFi raises FY23 adjusted EPS view to 28c-35c from 26c-33c, consensus 28c 05/11/23 OppFi reports Q1 adjusted EPS 5c, consensus (1c) 03/23/23 OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) OPFI OppFi $2.06 / +0.05 (+2.49%) 05/11/23 Fly Intel: After-Hours Movers 03/23/23 Fly Intel: After-Hours Movers 06/07/23 OppFi Inc
On The Fly	Fly Intel: After-Hours Movers » 19:26 05/11/23 05/11 19:26 05/11/23 19:26 BLBD Blue Bird $19.31 / -0.06 (-0.31%) , OPFI OppFi $2.06 / +0.05 (+2.49%) , SURG SurgePays $4.46 / -0.13 (-2.83%) , AMLX Amylyx $28.85 / -0.05 (-0.17%) , NWS News Corp. $16.83 / -0.02 (-0.12%) , NWSA News Corp. $16.74 / +0.08 (+0.48%) , IONQ IonQ $7.03 / +0.085 (+1.22%) , HROW Harrow Health $27.03 / -0.82 (-2.94%) , WEST Westrock Coffee $11.63 / -0.02 (-0.17%) , SOUN SoundHound $2.55 / +0.005 (+0.20%) … Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options WEST SURG NWSA NWS IONQ HROW BLBD AMLX WEST Westrock Coffee $11.63 / -0.02 (-0.17%) 03/06/23 Westrock Coffee moves headquarters to Little Rock 02/28/23 Westrock Coffee to acquire Bixby Roasting Co, terms not stated 12/22/22 Westrock Coffee down 25% after filing to sell 19.9M shares issuable by warrants SURG SurgePays $4.46 / -0.13 (-2.83%) 05/11/23 SurgePays jumps 19% to $5.23 after Q1 results and guidance 05/08/23 SurgePays commences trading on Upstream 05/02/23 SurgePays approved to dual list on Upstream 04/17/23 Mace Security enters distribution agreement with SurgePays NWSA News Corp. $16.74 / +0.08 (+0.48%) 01/24/23 Irenic Capital comments on withdrawal of proposal to combine News Corp, Fox 01/24/23 Rupert Murdoch withdrawing proposal for Fox Corp, News Corp. combination NWS News Corp. $16.83 / -0.02 (-0.12%) 02/21/23 News Corp no longer in discussions with CoStar over potential Move sale 02/14/23 Greenlight buys Tenet, exits Intel in Q4 02/14/23 Elliott buys NiSource, cuts Aerojet in Q4 01/30/23 Barron's appoints Andy Serwer as editor at large IONQ IonQ $7.03 / +0.085 (+1.22%) 04/26/23 IonQ announces pact with UAE Quantum Research Center 04/04/23 IonQ rises 11.5% 03/31/23 IonQ rises 29.9% 03/31/23 IonQ rises 21.9% HROW Harrow Health $27.03 / -0.82 (-2.94%) 03/28/23 Harrow Health announces new $100M secured credit facility with Oaktree 03/13/23 Harrow Health announces CMS approval for reimbursement status for Iheezo 3% 03/13/23 Harrow gets transitional pass-through reimbursement status for IHEEZO from CMS 02/22/23 Harrow Health dips 4% after Bonitas publishes short report BLBD Blue Bird $19.31 / -0.06 (-0.31%) 05/11/23 Blue Bird jumps 13% to $21.75 after Q2 earnings beat, raised guidance 01/19/23 Blue Bird partners with Gregory Poole Bus Sales & Service for South Carolina 12/08/22 Blue Bird partners with Highland Electric Fleets for 12 electric school buses AMLX Amylyx $28.85 / -0.05 (-0.17%) 04/13/23 Amylyx: First person dosed in AMX0035 trial for Wolfram Syndrome treatment 02/02/23 Amylyx completes enrollment in global Phase 3 trial of AMX0035 in ALS BLBD OPFI SURG AMLX NWS NWSA IONQ HROW WEST SOUN BLBD Blue Bird $19.31 / -0.06 (-0.31%) 04/04/23 DA Davidson Blue Bird price target raised to $23 from $17 at DA Davidson 02/09/23 Craig-Hallum Blue Bird price target raised to $23 from $16 at Craig-Hallum 02/09/23 DA Davidson Blue Bird price target raised to $17 from $14.50 at DA Davidson 12/06/22 DA Davidson Blue Bird price target raised to $14.50 from $13.50 at DA Davidson OPFI OppFi $2.06 / +0.05 (+2.49%) 03/24/23 DA Davidson OppFi price target lowered to $2.50 from $3 at DA Davidson 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson SURG SurgePays $4.46 / -0.13 (-2.83%) 12/01/22 Maxim SurgePays price target raised to $15 from $10 at Maxim AMLX Amylyx $28.85 / -0.05 (-0.17%) 03/30/23 Mizuho Amylyx initiated with a Buy at Mizuho 03/14/23 Citi Amylyx price target raised to $54 from $51 at Citi 01/05/23 BofA BofA starts Amylyx with a Buy given 'huge unmet need' in ALS 01/05/23 BofA Amylyx initiated with a Buy at BofA NWS News Corp. $16.83 / -0.02 (-0.12%) 07/10/22 Goldman Sachs News Corp. downgraded to Buy from Conviction Buy at Goldman Sachs NWSA News Corp. $16.74 / +0.08 (+0.48%) 01/25/23 Loop Capital Fox upgraded to Buy with $40 price target at Loop Capital 01/25/23 Loop Capital Loop upgrades News Corp. to Buy on ending of Fox tie-up 01/25/23 Loop Capital News Corp. upgraded to Buy from Hold at Loop Capital 10/17/22 Morgan Stanley Morgan Stanley says Fox-News combo would balance more scale with more complexity IONQ IonQ $7.03 / +0.085 (+1.22%) 04/26/23 Morgan Stanley IonQ initiated with an Equal Weight at Morgan Stanley 11/16/22 Benchmark IonQ price target lowered to $8 from $12 at Benchmark 08/16/22 Benchmark IonQ price target lowered to $12 from $15 at Benchmark 07/15/22 Goldman Sachs IonQ price target lowered to $8 from $10 at Goldman Sachs HROW Harrow Health $27.03 / -0.82 (-2.94%) 04/17/23 Lake Street Harrow Health price target raised to $37 from $24 at Lake Street 01/24/23 Lake Street Harrow Health price target raised to $24 from $17 at Lake Street 01/05/23 B. Riley Harrow Health price target raised to $22 from $17 at B. Riley 10/03/22 Lake Street Lake Street affirms Buy rating on Harrow Health after 'big' week WEST Westrock Coffee $11.63 / -0.02 (-0.17%) 04/13/23 Stifel Westrock Coffee resumed with a Buy at Stifel 09/23/22 Stifel Westrock Coffee initiated with a Buy at Stifel 09/21/22 Stephens Westrock Coffee initiated with an Overweight at Stephens 07/21/22 Benchmark Riverview Acquisition initiated with a Buy at Benchmark SOUN SoundHound $2.55 / +0.005 (+0.20%) 03/08/23 Cantor Fitzgerald SoundHound price target raised to $3.20 from $1.60 at Cantor Fitzgerald 01/06/23 Northland SoundHound price target lowered to $4.50 from $6 at Northland 11/30/22 Cantor Fitzgerald SoundHound upgraded to Overweight from Neutral at Cantor Fitzgerald 11/30/22 Cantor Fitzgerald SoundHound upgraded to Overweight from Neutral at Cantor Fitzgerald WEST SURG SOUN OPFI NWS IONQ HROW BLBD AMLX WEST Westrock Coffee $11.63 / -0.02 (-0.17%) 05/11/23 Westrock Coffee reports Q1 EPS (13c), consensus (1c) SURG SurgePays $4.46 / -0.13 (-2.83%) 05/11/23 SurgePays backs FY23 revenue view of 'at least' $190M, two estimates $197.8M 05/11/23 SurgePays reports Q1 EPS 31c, two estimates (3c) 03/02/23 SurgePays sees Q4 revenue $35M-$36M SOUN SoundHound $2.55 / +0.005 (+0.20%) 05/11/23 SoundHound continues to see FY23 revenue $43M-$50M, consensus $45.93M 05/11/23 SoundHound reports Q1 EPS (13c), consensus (12c) 03/07/23 SoundHound sees FY23 revenue $43M-$50M, consensus $46.05M 03/07/23 SoundHound reports Q4 EPS (15c), consensus (17c) OPFI OppFi $2.06 / +0.05 (+2.49%) 05/11/23 OppFi raises FY23 adjusted EPS view to 28c-35c from 26c-33c, consensus 28c 05/11/23 OppFi reports Q1 adjusted EPS 5c, consensus (1c) 03/23/23 OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) NWS News Corp. $16.83 / -0.02 (-0.12%) 05/11/23 News Corp. reports Q3 EPS 9c vs. 16c last year 02/09/23 News Corp. reports Q2 adjusted EPS 14c vs 44c last year IONQ IonQ $7.03 / +0.085 (+1.22%) 05/11/23 IonQ raises FY23 revenue view to $18.8M-$19.2M, consensus $18.6M 05/11/23 IonQ sees Q revenue $4.1M-$4.5M, consensus $4.3M 05/11/23 IonQ reports Q1 EPS (14c), consensus (11c) 03/30/23 IonQ sees FY23 revenue $18.4M-$18.8M, consensus $18.2M HROW Harrow Health $27.03 / -0.82 (-2.94%) 05/11/23 Harrow Health backs FY23 revenue view $135M-$145M, consensus $137.06M 05/11/23 Harrow Health reports Q1 core EPS (3c), consensus (5c) 03/23/23 Harrow Health reports Q4 core EPS 7c, consensus (12c) 11/14/22 Harrow Health reports Q3 core EPS (6c), consensus 0c BLBD Blue Bird $19.31 / -0.06 (-0.31%) 05/11/23 Blue Bird raises FY23 revenue view to 'just over $1.1B', consensus $1.02B 05/11/23 Blue Bird reports Q2 adjusted non-GAAP EPS 27c, consensus 8c 05/11/23 Blue Bird reports Q2 EPS 22c, consensus 8c 02/08/23 Blue Bird raises FY23 revenue view to 'just over $1B', consensus $959.8M AMLX Amylyx $28.85 / -0.05 (-0.17%) 05/11/23 Amylyx reports Q1 EPS 2c, consensus (24c) 03/13/23 Amylyx reports Q4 EPS (65c), consensus (82c) 14 Dec 07 Oct NWSA NWS IONQ HROW NWSA News Corp. $16.74 / +0.08 (+0.48%) 01/25/23 National Association of Realtors a hurdle for Move Inc. sale, Bloomberg says 01/12/23 News Corp. CEO requests that workers return to office, Bloomberg reports NWS News Corp. $16.83 / -0.02 (-0.12%) 02/27/23 Murdoch says Fox News hosts endorsed false election narrative, NYT says 01/24/23 News Corp. in discussions to sell 80% Move stake to CoStar, FT reports 12/23/22 Michael Bloomberg eyeing Dow Jones, Washington Post, Axios reports IONQ IonQ $7.03 / +0.085 (+1.22%) 11/26/22 Quantum stocks to be challenged to generate significant revenue, Barron's says HROW Harrow Health $27.03 / -0.82 (-2.94%) 02/22/23 Harrow Health named a short idea by Bonitas Research SOUN OPFI NWS IONQ BLBD AMLX SOUN SoundHound $2.55 / +0.005 (+0.20%) 03/08/23 What You Missed On Wall Street On Wednesday 03/08/23 What You Missed On Wall Street This Morning 03/07/23 Fly Intel: After-Hours Movers 11/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations OPFI OppFi $2.06 / +0.05 (+2.49%) 03/23/23 Fly Intel: After-Hours Movers NWS News Corp. $16.83 / -0.02 (-0.12%) 02/22/23 What You Missed On Wall Street On Wednesday 02/22/23 What You Missed On Wall Street This Morning 02/10/23 What You Missed On Wall Street On Friday 02/10/23 What You Missed On Wall Street This Morning IONQ IonQ $7.03 / +0.085 (+1.22%) 03/31/23 What You Missed On Wall Street On Friday 03/31/23 What You Missed On Wall Street This Morning BLBD Blue Bird $19.31 / -0.06 (-0.31%) 02/08/23 Fly Intel: After-Hours Movers 12/12/22 Fly Intel: After-Hours Movers AMLX Amylyx $28.85 / -0.05 (-0.17%) 03/14/23 What You Missed On Wall Street On Tuesday 03/14/23 What You Missed On Wall Street This Morning 03/14/23 Fly Intel: Pre-market Movers 03/13/23 Fly Intel: After-Hours Movers 09/19/23 Institutional Investor Conference 2023 05/11/23 IonQ - IONQ 05/11/23 Westrock Coffee - WEST 05/11/23 OppFi - OPFI 05/11/23 Amylyx - AMLX 05/11/23 Blue Bird - BLBD 05/11/23 Harrow Health - HROW 05/11/23 News Corp. - NWSA 05/11/23 News Corp. - NWS 05/11/23 SurgePays - SURG 05/11/23 SoundHound - SOUN 06/07/23 IonQ Inc 06/07/23 OppFi Inc 06/08/23 Amylyx Pharmaceuticals, Inc. 06/08/23 Westrock Coffee Company 06/21/23 Harrow Health Inc WEST SOUN NWSA IONQ AMLX WEST Westrock Coffee $11.63 / -0.02 (-0.17%) 03/14/23 Westrock Coffee options imply 5.9% move in share price post-earnings 01/04/23 Largest borrow rate increases among liquid names SOUN SoundHound $2.55 / +0.005 (+0.20%) 05/11/23 SoundHound AI options imply 13.2% move in share price post-earnings 04/21/23 Largest borrow rate increases among liquid names 04/20/23 Largest borrow rate increases among liquid names 04/11/23 Largest borrow rate increases among liquid names NWSA News Corp. $16.74 / +0.08 (+0.48%) 01/25/23 Early notable gainers among liquid option names on January 25th 12/28/22 Early notable gainers among liquid option names on December 28th IONQ IonQ $7.03 / +0.085 (+1.22%) 05/11/23 IONQ options imply 11.3% move in share price post-earnings 03/30/23 IONQ options imply 7.2% move in share price post-earnings 02/17/23 Largest borrow rate increases among liquid names 02/16/23 Largest borrow rate increases among liquid names AMLX Amylyx $28.85 / -0.05 (-0.17%) 03/13/23 Amylyx Pharmaceuticals options imply 16.5% move in share price post-earnings
Earnings	OppFi raises FY23 adjusted EPS view to 28c-35c from 26c-33c, consensus 28c » 16:06 05/11/23 05/11 16:06 05/11/23 16:06 OPFI OppFi $2.02 / +0.01 (+0.50%) Backs FY23 revenue view… Backs FY23 revenue view $500M-$520M, consensus $509.77M. ShowHide Related Items >><< Street Research Earnings On The Fly Events OPFI OppFi $2.02 / +0.01 (+0.50%) 03/24/23 DA Davidson OppFi price target lowered to $2.50 from $3 at DA Davidson 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson OPFI OppFi $2.02 / +0.01 (+0.50%) 05/11/23 OppFi reports Q1 adjusted EPS 5c, consensus (1c) 03/23/23 OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) OPFI OppFi $2.02 / +0.01 (+0.50%) 03/23/23 Fly Intel: After-Hours Movers 05/11/23 OppFi - OPFI 06/07/23 OppFi Inc
Earnings	OppFi reports Q1 adjusted EPS 5c, consensus (1c) » 16:06 05/11/23 05/11 16:06 05/11/23 16:06 OPFI OppFi $2.02 / +0.01 (+0.50%) Reports Q1 revenue… Reports Q1 revenue $120.4M, consensus $116.74M. "I am very pleased to report continued strength in our business," said Todd Schwartz, Chief Executive Officer and Executive Chairman of OppFi. "In the first quarter of 2023, we achieved adjusted net income that exceeded our guidance with solid year over year growth." ShowHide Related Items >><< Street Research Earnings On The Fly Events OPFI OppFi $2.02 / +0.01 (+0.50%) 03/24/23 DA Davidson OppFi price target lowered to $2.50 from $3 at DA Davidson 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson OPFI OppFi $2.02 / +0.01 (+0.50%) 03/23/23 OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) OPFI OppFi $2.02 / +0.01 (+0.50%) 03/23/23 Fly Intel: After-Hours Movers 05/11/23 OppFi - OPFI 06/07/23 OppFi Inc

Over a month ago
Recommendations	OppFi price target lowered to $2.50 from $3 at DA Davidson » 08:06 03/24/23 03/24 08:06 03/24/23 08:06 OPFI OppFi $1.90 / +0.11 (+6.15%) DA Davidson analyst… DA Davidson analyst Christopher Brendler lowered the firm's price target on OppFi to $2.50 from $3 and keeps a Neutral rating on the shares. The company reported "another relatively impressive quarter" and its initial 2023 guidance exceeded expectations, the analyst tells investors in a research note. However, OppFi's credit remains an issue and given increasing recession risk, investors should wait for better visibility, says the firm. ShowHide Related Items >><< Street Research Earnings On The Fly OPFI OppFi $1.90 / +0.11 (+6.15%) 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson OPFI OppFi $1.90 / +0.11 (+6.15%) 03/23/23 OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) 11/09/22 OppFi backs FY22 revenue growth view 20%-25%, consensus $429.57M 11/09/22 OppFi reports Q3 adjusted EPS 1c, consensus (6c) OPFI OppFi $1.90 / +0.11 (+6.15%) 03/23/23 Fly Intel: After-Hours Movers
On The Fly	Fly Intel: After-Hours Movers » 18:53 03/23/23 03/23 18:53 03/23/23 18:53 CURV Torrid $2.38 / +0.05 (+2.15%) , OPFI OppFi $1.90 / +0.11 (+6.15%) , HRTX Heron Therapeutics $2.07 / +0.105 (+5.36%) , RGLS Regulus $1.05 / -0.01 (-0.94%) , EAR Eargo $4.66 / +0.385 (+9.01%) , ERAS Erasca $2.78 / -0.135 (-4.63%) , CYT Cyteir Therapeutics $1.76 / +0.095 (+5.72%) , SWX Southwest Gas $59.42 / -1.235 (-2.04%) , SCHL Scholastic $41.28 / -1.24 (-2.92%) , QRHC Quest Resource $6.22 / +0.28 (+4.71%) , OUST Ouster / + , OXM Oxford Industries $116.71 / -0.87 (-0.74%) , JOAN Joann $2.13 / +0.15 (+7.58%) , RLMD Relmada Therapeutics $2.31 / -0.035 (-1.50%) … Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options SWX SCHL RLMD RGLS QRHC OXM OUST JOAN HRTX ERAS EAR CYT CURV SWX Southwest Gas $59.42 / -1.235 (-2.04%) 03/23/23 Carl Icahn increases stake in Southwest Gas by $31.6M 03/14/23 Carl Icahn increases stake in Southwest Gas by $32M 03/10/23 Icahn Enterprises raises Southwest Gas stake to 12.64% from 9.9% 12/15/22 Williams to acquire MountainWest from Southwest Gas for $1.5B SCHL Scholastic $41.28 / -1.24 (-2.92%) 03/23/23 Scholastic falls 11% to $36.90 after lowering FY23 guidance 03/23/23 Scholastic board authorizes additional $50M for share repurchases 02/22/23 Scholastic announces strategic partnership with SoapBox Labs 12/15/22 Scholastic raises share repurchase authorization to $75M RLMD Relmada Therapeutics $2.31 / -0.035 (-1.50%) 01/09/23 Relmada Therapeutics names Cedric O'Gorman MD as Chief Medical Officer 12/07/22 Relmada Therapeutics trading resumes 12/07/22 Relmada Therapeutics' REL-1017 in depressive disorder did not reach endpoint 12/07/22 Relmada Therapeutics trading halted, news pending RGLS Regulus $1.05 / -0.01 (-0.94%) 12/12/22 Regulus announces resignation of board member 11/29/22 Regulus adds Rekha Garg and Claire Padgett to scientific leadership team 11/02/22 Regulus doses first patient in Phase 1b MAD study of RGSL8429 QRHC Quest Resource $6.22 / +0.28 (+4.71%) 10/12/22 Quest Resource appoints Brett Johnston as CFO OXM Oxford Industries $116.71 / -0.87 (-0.74%) 03/23/23 Oxford Industries increases quarterly cash dividend 18% to 55c per share OUST Ouster / + 03/21/23 Ouster and LASE GmbH in multi-year deal to automate port operation 03/16/23 Ouster expands infrastructure programs with over 210 awarded projects 02/01/23 Ouster, Velodyne Lidar achieve guidance, announce combined board of directors 01/24/23 Velodyne Lidar has not yet reached stockholder votes required for Ouster merger JOAN Joann $2.13 / +0.15 (+7.58%) 03/13/23 Joann announces $100M FILO credit facility 10/10/22 Joann, Sutton Foster team up for World Mental Health Day HRTX Heron Therapeutics $2.07 / +0.105 (+5.36%) 03/13/23 Heron announces CMS granted pass-through payment status for APONVIE 03/13/23 Heron says CMS granted pass-through payment status for Aponvie 03/06/23 Heron Therapeutics announces U.S. commercial launch of APONVIE 02/22/23 Heron Therapeutics announces cooperation agreement with Rubric and Velan ERAS Erasca $2.78 / -0.135 (-4.63%) 12/20/22 Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/13/22 Erasca announces FDA clearance of IND application for ERAS-3490 12/09/22 Erasca announces pricing of underwritten offering of common stock 12/09/22 Erasca, Novartis enter worldwide license agreement for naporafenib EAR Eargo $4.66 / +0.385 (+9.01%) 02/06/23 Nasdaq confirms Eargo's minimum bid price deficiency 'cured' 01/11/23 Eargo announces 1-for-20 reverse stock split 01/11/23 Eargo to complete a 1-for-20 reverse stock split 12/12/22 Eargo to partner with NationsBenefits on over-the-counter hearing aids CYT Cyteir Therapeutics $1.76 / +0.095 (+5.72%) 02/06/23 Cyteir Therapeutics promotes David Gaiero to CFO 01/19/23 Cyteir Therapeutics announces prioritization of CYT-0851 development CURV Torrid $2.38 / +0.05 (+2.15%) 03/23/23 Torrid names Mark Mizicko as Chief Commercial Officer 12/16/22 Torrid rises 9.9% 12/09/22 Torrid falls -15.7% 12/09/22 Torrid falls -19.0% CURV OPFI HRTX RGLS EAR ERAS CYT SWX SCHL QRHC OUST OXM JOAN RLMD CURV Torrid $2.38 / +0.05 (+2.15%) 02/15/23 Jefferies Torrid downgraded to Hold from Buy at Jefferies 12/09/22 William Blair William Blair downgrades Torrid on larger than thought overhang 12/09/22 Morgan Stanley Torrid assumed with an Equal Weight at Morgan Stanley 12/09/22 William Blair Torrid downgraded to Market Perform from Outperform at William Blair OPFI OppFi $1.90 / +0.11 (+6.15%) 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson HRTX Heron Therapeutics $2.07 / +0.105 (+5.36%) 06/15/22 Evercore ISI Crinetics added to Best SMID 'Core' Ideas list at Evercore ISI 05/10/22 Cantor Fitzgerald Heron Therapeutics price target lowered to $12 from $20 at Cantor Fitzgerald 05/10/22 TD Cowen Heron Therapeutics price target lowered to $7.50 from $13 at Cowen RGLS Regulus $1.05 / -0.01 (-0.94%) 11/07/22 Canaccord Regulus initiated with a Buy at Canaccord EAR Eargo $4.66 / +0.385 (+9.01%) ERAS Erasca $2.78 / -0.135 (-4.63%) 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley CYT Cyteir Therapeutics $1.76 / +0.095 (+5.72%) 02/03/23 Morgan Stanley Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral from Buy at BofA 01/20/23 JPMorgan Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan SWX Southwest Gas $59.42 / -1.235 (-2.04%) 02/07/23 JPMorgan Southwest Gas price target lowered to $75 from $78 at JPMorgan 12/14/22 Wells Fargo Southwest Gas price target raised to $73 from $66 at Wells Fargo 11/30/22 BofA Southwest Gas downgraded to Neutral at BofA as strategic review 'drags on' 11/30/22 BofA Southwest Gas downgraded to Neutral from Buy at BofA SCHL Scholastic $41.28 / -1.24 (-2.92%) QRHC Quest Resource $6.22 / +0.28 (+4.71%) 04/18/22 EF Hutton Quest Resource initiated with a Buy at EF Hutton OUST Ouster / + 12/07/22 Citi Ouster downgraded to Neutral from Buy at Citi 11/09/22 Oppenheimer Velodyne Lidar downgraded to Perform from Outperform at Oppenheimer 11/09/22 Craig-Hallum Velodyne Lidar upgraded to Hold from Sell at Craig-Hallum 11/08/22 Baird Ouster downgraded to Neutral from Outperform at Baird OXM Oxford Industries $116.71 / -0.87 (-0.74%) 01/30/23 KeyBanc Oxford Industries price target raised to $130 from $125 at KeyBanc 12/08/22 CL King Oxford Industries price target raised to $140 from $137 at CL King 12/08/22 Citi Oxford Industries price target raised to $110 from $105 at Citi 09/21/22 Citi Oxford Industries upgraded to Neutral from Sell at Citi JOAN Joann $2.13 / +0.15 (+7.58%) 12/14/22 Barclays Joann price target lowered to $3 from $5 at Barclays 12/13/22 Loop Capital Joann price target lowered to $4 from $7 at Loop Capital 09/02/22 Wells Fargo Joann price target lowered to $4 from $5 at Wells Fargo 08/31/22 BofA BofA downgrades Joann to Underperform on signs of slowing arts & crafts demand RLMD Relmada Therapeutics $2.31 / -0.035 (-1.50%) 12/08/22 Truist Relmada Therapeutics price target lowered to $4 from $7 at Truist 11/11/22 SVB Securities Relmada 'still has a chance' for positive depression data, says SVB 10/14/22 BofA Axsome shares could react positively to Relmada trial failure, says BofA 10/14/22 Goldman Sachs Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs SWX SCHL RLMD RGLS QRHC OXM OUST OPFI JOAN HRTX ERAS EAR CYT CURV SWX Southwest Gas $59.42 / -1.235 (-2.04%) 02/28/23 Southwest Gas reports Q4 adjusted EPS $1.16, consensus $1.58 11/09/22 Southwest Gas reports Q3 adjusted EPS (5c), consensus 27c SCHL Scholastic $41.28 / -1.24 (-2.92%) 03/23/23 Scholastic cuts FY23 revenue growth view to about 4% from 8%-10% 03/23/23 Scholastic reports Q3 EPS (57c) vs. (44c) last year 12/15/22 Scholastic backs FY23 revenue growth 8%-10% 12/15/22 Scholastic reports Q2 EPS $2.12 vs. $1.91 a year ago RLMD Relmada Therapeutics $2.31 / -0.035 (-1.50%) 03/23/23 Relmada Therapeutics reports Q4 EPS ($1.28), consensus ($1.33) 11/10/22 Relmada Therapeutics reports Q3 EPS ($1.31), consensus ($1.45) RGLS Regulus $1.05 / -0.01 (-0.94%) 03/23/23 Regulus reports Q4 EPS (40c), consensus (51c) 11/10/22 Regulus reports Q3 EPS (50c), consensus (49c) QRHC Quest Resource $6.22 / +0.28 (+4.71%) 03/23/23 Quest Resource reports Q4 EPS (2c), consensus (5c) 11/14/22 Quest Resource reports Q3 EPS 4c, consensus (3c) OXM Oxford Industries $116.71 / -0.87 (-0.74%) 03/23/23 Oxford Industries sees FY23 adjusted EPS $11.50-$11.90, consensus $11.82 03/23/23 Oxford Industries sees Q1 adjusted EPS $3.60-$3.80, consensus $4.10 03/23/23 Oxford Industries reports Q4 adjusted EPS $2.28, consensus 12/07/22 Oxford raises FY22 adjusted EPS view to $10.60-$10.75 from $10.25-$10.60 OUST Ouster / + 03/23/23 Ouster sees Q1 revenue $15M-$17M, consensus $20.1M 03/23/23 Ouster reports Q4 EPS (23c), consensus (18c) 11/07/22 Ouster backs FY22 revenue view $40M-$55M, consensus $46.14M 11/07/22 Ouster reports Q3 EPS (20c), consensus (17c) OPFI OppFi $1.90 / +0.11 (+6.15%) 03/23/23 OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) 11/09/22 OppFi backs FY22 revenue growth view 20%-25%, consensus $429.57M 11/09/22 OppFi reports Q3 adjusted EPS 1c, consensus (6c) JOAN Joann $2.13 / +0.15 (+7.58%) 03/23/23 Joann reports Q4 EPS 7c, may not compare to consensus 70c 12/12/22 Joann reports Q3 adjusted EPS 6c, consensus 23c HRTX Heron Therapeutics $2.07 / +0.105 (+5.36%) 03/23/23 Heron Therapeutics reports Q4 EPS (17c), consensus (28c) 11/08/22 Heron Therapeutics reports Q3 EPS (38c), consensus (38c) ERAS Erasca $2.78 / -0.135 (-4.63%) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year 11/09/22 Erasca reports Q3 EPS (29c), consensus (31c) EAR Eargo $4.66 / +0.385 (+9.01%) 03/23/23 Eargo reports Q4 EPS ($4.18) vs ($17.11) last year CYT Cyteir Therapeutics $1.76 / +0.095 (+5.72%) 03/23/23 Cyteir Therapeutics reports Q4 EPS (25c), consensus (34c) 11/07/22 Cyteir Therapeutics reports Q3 EPS (31c), consensus (41c) CURV Torrid $2.38 / +0.05 (+2.15%) 03/23/23 Torrid sees FY23 revenue $$.125B-$1.32B, consensus $1.26B 03/23/23 Torrid sees Q1 revenue $305M-$313M, consensus $315.6M 03/23/23 Torrid reports Q4 EPS (4c), consensus (8c) 12/08/22 Torrid cuts FY22 revenue view to $1.244B-$1.259B from $1.26B-$1.3B 08 Mar 09 Dec 29 Mar SWX RLMD QRHC OXM OUST JOAN ERAS CURV SWX Southwest Gas $59.42 / -1.235 (-2.04%) 03/20/23 Fly Insider: Southwest Gas, Pathward among week's notable insider trades 03/14/23 Fly Intel: After-Hours Movers RLMD Relmada Therapeutics $2.31 / -0.035 (-1.50%) 03/23/23 Here's What You Missed in Cannabis, Psychedelics This Week 03/09/23 Rising High: Exclusive talk with cannabinoid market research firm BDSA 03/02/23 Rising High: Exclusive talk with vertically-integrated MSO Greenlight 02/23/23 Rising High: Exclusive talk with funding solutions provider FundCanna QRHC Quest Resource $6.22 / +0.28 (+4.71%) 11/14/22 Fly Intel: After-Hours Movers OXM Oxford Industries $116.71 / -0.87 (-0.74%) 12/07/22 Fly Intel: After-Hours Movers OUST Ouster / + 11/14/22 What You Missed This Week in EVs and Clean Energy 11/07/22 What You Missed On Wall Street On Monday 11/07/22 What You Missed On Wall Street This Morning 11/07/22 What You Missed This Week in EVs and Clean Energy JOAN Joann $2.13 / +0.15 (+7.58%) 12/12/22 Fly Intel: After-Hours Movers ERAS Erasca $2.78 / -0.135 (-4.63%) 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning CURV Torrid $2.38 / +0.05 (+2.15%) 02/15/23 What You Missed On Wall Street This Morning 12/08/22 Fly Intel: After-Hours Movers 03/23/23 Heron Therapeutics - HRTX 03/23/23 Scholastic - SCHL 03/23/23 Torrid - CURV 03/23/23 Oxford Industries - OXM 03/23/23 Relmada Therapeutics - RLMD 03/23/23 Eargo - EAR 03/23/23 OppFi - OPFI 03/23/23 Ouster - OUST 03/23/23 Quest Resource - QRHC 03/23/23 Joann - JOAN 05/04/23 Southwest Gas Holdings Inc RLMD JOAN RLMD Relmada Therapeutics $2.31 / -0.035 (-1.50%) 11/11/22 Relmada Therapeutics call volume above normal and directionally bullish 11/10/22 Relmada Therapeutics put volume heavy and directionally bearish 10/07/22 Relmada Therapeutics put volume heavy and directionally bearish JOAN Joann $2.13 / +0.15 (+7.58%) 12/19/22 Largest borrow rate increases among liquid names 12/12/22 JOANN options imply 19.6% move in share price post-earnings
Earnings	OppFi sees FY23 adjusted EPS 26c-33c, consensus 24c » 16:08 03/23/23 03/23 16:08 03/23/23 16:08 OPFI OppFi $1.79 / + (+0.00%) Sees FY23 revenue… Sees FY23 revenue $500M-$520M, consensus $439.81M. ShowHide Related Items >><< Street Research Earnings Events OPFI OppFi $1.79 / + (+0.00%) 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson OPFI OppFi $1.79 / + (+0.00%) 03/23/23 OppFi reports Q4 adjusted EPS (19c), consensus (10c) 11/09/22 OppFi backs FY22 revenue growth view 20%-25%, consensus $429.57M 11/09/22 OppFi reports Q3 adjusted EPS 1c, consensus (6c) 10/25/22 OppFi sees Q3 revenue $124.2M, consensus $108.8M 03/23/23 OppFi - OPFI
Earnings	OppFi reports Q4 adjusted EPS (19c), consensus (10c) » 16:07 03/23/23 03/23 16:07 03/23/23 16:07 OPFI OppFi $1.79 / + (+0.00%) Reports Q4 revenue… Reports Q4 revenue $120.03M, consensus $109.73M. "We delivered record net originations, total revenue and ending receivables in 2022. As a result, we achieved our eighth consecutive year of profitability, exceeding our guidance," said Todd Schwartz, Chief Executive Officer and Executive Chairman of OppFi. "We are optimistic about 2023, while remaining mindful of the continuation of an uncertain macroeconomic environment," continued Schwartz. "Based on credit adjustments that we implemented in 2022 and our 10-year business history, we are confident that we can control our success by balancing origination growth, overall risk, and expenses. First payment default and the total delinquency rates have continued to improve in the first quarter of 2023. As a result, we expect adjusted net income to rebound significantly this year, as demonstrated by our full-year guidance." ShowHide Related Items >><< Street Research Earnings Events OPFI OppFi $1.79 / + (+0.00%) 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson OPFI OppFi $1.79 / + (+0.00%) 11/09/22 OppFi backs FY22 revenue growth view 20%-25%, consensus $429.57M 11/09/22 OppFi reports Q3 adjusted EPS 1c, consensus (6c) 10/25/22 OppFi sees Q3 revenue $124.2M, consensus $108.8M 03/23/23 OppFi - OPFI

Over a quarter ago
Earnings	OppFi backs FY22 revenue growth view 20%-25%, consensus $429.57M 16:46 11/09/22 11/09 16:46 11/09/22 16:46 OPFI OppFi $1.88 / -0.255 (-11.94%) ShowHide Related Items >><< Company News Street Research Earnings Events OPFI OppFi $1.88 / -0.255 (-11.94%) 06/27/22 OppFi announces addition to Russell 2000 Index 06/15/22 OppFi implements 10b5-1 trading plan as part of share repurchase program OPFI OppFi $1.88 / -0.255 (-11.94%) 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson 03/11/22 Needham OppFi price target lowered to $4.50 from $10 at Needham 03/11/22 JMP Securities OppFi price target lowered to $6 from $10 at JMP Securities OPFI OppFi $1.88 / -0.255 (-11.94%) 11/09/22 OppFi reports Q3 adjusted EPS 1c, consensus (6c) 10/25/22 OppFi sees Q3 revenue $124.2M, consensus $108.8M 08/09/22 OppFi reaffirms FY22 revenue growth 20%-25%, consensus $426.92M 08/09/22 OppFi reports Q2 adjusted EPS 8c, consensus 6c 11/09/22 OppFi - OPFI
Earnings	OppFi reports Q3 adjusted EPS 1c, consensus (6c) » 16:46 11/09/22 11/09 16:46 11/09/22 16:46 OPFI OppFi $1.88 / -0.255 (-11.94%) Reports Q3 revenue… Reports Q3 revenue $124.2M, consensus $108.76M. "We are pleased with our performance in the third quarter, which was in-line with our expectations," said Todd Schwartz, Chief Executive Officer and Executive Chairman of OppFi. "Following the most significant adjustments to credit models in our company's history, we ended the quarter with substantially lower early delinquency rates sequentially for both new and refinanced loans. In addition, we extended operational efficiencies, as demonstrated by the solid scaling of our expense structure." ShowHide Related Items >><< Company News Street Research Earnings Events OPFI OppFi $1.88 / -0.255 (-11.94%) 06/27/22 OppFi announces addition to Russell 2000 Index 06/15/22 OppFi implements 10b5-1 trading plan as part of share repurchase program OPFI OppFi $1.88 / -0.255 (-11.94%) 08/11/22 DA Davidson OppFi cut to Neutral at DA Davidson yesterday after pulling FY22 profit outlook 08/10/22 DA Davidson OppFi downgraded to Neutral from Buy at DA Davidson 03/11/22 Needham OppFi price target lowered to $4.50 from $10 at Needham 03/11/22 JMP Securities OppFi price target lowered to $6 from $10 at JMP Securities OPFI OppFi $1.88 / -0.255 (-11.94%) 10/25/22 OppFi sees Q3 revenue $124.2M, consensus $108.8M 08/09/22 OppFi reaffirms FY22 revenue growth 20%-25%, consensus $426.92M 08/09/22 OppFi reports Q2 adjusted EPS 8c, consensus 6c 11/09/22 OppFi - OPFI

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial